Q&A: Jessica Alber, Ph.D.

Her inspiration, the biggest challenges in her work, and what makes her feel hopeful. Assistant Professor Jessica Alber investigates the potential to use retinal imaging as a screening tool for early-stage Alzheimer’s disease. Performed during a routine eye exam, the screening technique could help provide a low-cost, minimally invasive way to detect Alzheimer’s disease before […]

Continue reading "Q&A: Jessica Alber, Ph.D."

Q&A: The risks of brain bleeds in antibody treatments for Alzheimer’s disease

Ryan Institute Co-Executive Director William Van Nostrand answers questions about the potential risk of brain bleeds associated with newly-approved lecanemab and similar treatments. This summer, the FDA granted full approval to lecanemab, an antibody treatment for Alzheimer’s disease.  The antibody—a protein that works by clearing amyloid-beta protein “plaques” in the brain, a signature of Alzheimer’s disease—has […]

Continue reading "Q&A: The risks of brain bleeds in antibody treatments for Alzheimer’s disease"